22nd Jan 2026 07:00
22 January 2026
Scancell Holdings plc
("Scancell" or the "Company")
Notice of Interim Results and Investor Presentation
Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, will announce its interim financial results for the six months ended 31 October 2025 and provide a business update on progress achieved post-period, on Thursday 29 January 2026.
Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast for analysts and investors on the day of the results at 14:00 GMT.
If you would like to join the webcast, please follow this link:
Interim Financial Results for the six months ending 31 October 2025 | SparkLive | LSEG
For further information, please contact: | |
Scancell Holdings plc | +44 (0) 20 3709 5700 |
Phillip L'Huillier, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
| |
Panmure Liberum Limited (Nominated Advisor and Joint Broker) | +44 (0) 20 7886 2500 |
Emma Earl/ Will Goode, Mark Rogers (Corporate Finance) | |
Rupert Dearden (Corporate Broking)
| |
WG Partners LLP (Joint Broker) | +44 (0) 20 3705 9330 |
David Wilson, Claes Spang
| |
Investor and media relations | |
Mary-Ann Chang | +44 (0) 20 7483 284853
|
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified - enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
Related Shares:
Scancell Holdings